Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Plus Mifepristone in Metastatic CRPC
NCT02012296Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Dec 2013
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of mifepristone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Chicago. Started Dec 2013; status: completed.
02
Drugs
mifepristone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02012296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012296.